Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/31/26
End: 06/30/28
Due: 06/30/29
Phase: N/A
Priority: Normal
Start: 02/24/22
End: 09/11/23
Due: 09/11/24
Phase: N/A
Priority: Normal
Start: 09/01/19
End: 12/30/26
Due: 12/30/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma | NCT05039892 | 3D Medicines (Beijing) Co., Ltd. | user2@example.com | None | 2026-12-31 | 2028-06-30 | 2029-06-30 | - | - | 2025-07-14 |
| 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors | NCT05099536 | 3D Medicines (Beijing) Co., Ltd. | user2@example.com | None | 2022-02-24 | 2023-09-11 | 2024-09-11 | - | - | 2025-07-14 |
| A Monotherapy in Subjects With Advanced Solid Tumors | NCT04221204 | 3D Medicines (Beijing) Co., Ltd. | user2@example.com | None | 2019-09-01 | 2026-12-30 | 2027-12-30 | - | - | 2025-07-14 |